Promotional content developed and funded by Novartis Pharmaceuticals UK Ltd
for UK healthcare professionals only

Prescribing information Adverse event reporting information 

INGRAIN-MF
Incorporating genetics, risk and associated burden into MF management

Myelofibrosis (MF) is a progressive and debilitating disease.1 Patients have a considerably shortened life expectancy and experience substantial morbidity, including burdensome symptoms that affect their quality of life.1-3 MF is a heterogeneous disease, influenced by the genetic profile of the patient.4

Identifying genetic mutations, stratifying risk and monitoring symptom burden can help optimise treatment for each individual patient, according to their need.5-9

The INGRAIN-MF programme consists of four, short, CPD-accredited modules, designed to increase your awareness and understanding of the factors that influence disease manifestation and progression in MF, and the implications for managing and treating individual patients.

A certificate will be available to download upon completion of each module.

Module 1: The burden of myelofibrosis

Start

Module 2: The influence of genetic factors in myelofibrosis

Start

Module 3: A personalised approach to predicting prognosis in myelofibrosis

Start

Module 4: Optimising management of myelofibrosis and investigating the use of JAK inhibitors

Start

JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.10

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

References
  1. Zahr A A, Salama M E et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica 2016;101(6):660-671
  2. Harrison C N, Koschmieder S et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 2017;96(10):1653-1665
  3. Brunner A M, Hobbs G et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma 2016;57(5):1197-1200
  4. Rumi E, Pietra D et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014;124(7):1062-1069
  5. Knight E A, Osunsuyi-Fagbemi S, Neely J. Managing patients with myelofibrosis in the era of Janus kinase inhibitors. J Adv Pract Oncol 2015;6(6):532-550
  6. Cervantes F, Dupriez B et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-2901
  7. Loscocco G G, Guglielmelli P, Vannucchi A M. Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data. Onco Targets Ther 2020;13:12367-12382
  8. National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 386. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis, March 2016 (last reviewed July 2019). Available at: nice.org.uk. Accessed August 2025
  9. Kröger N M, Deeg J H et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 2015;29(11):2126-2133
  10. JAKAVI® Summary of Product Characteristics

© NICE 2016 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. Available from nice.org.uk/guidance/ta386. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.